Microbiological Techniques to Study Undue Strain Dominance Among Probiotic Bacteria in Order to Develop Compatible Multiple Mixed Probiotic Cultures to Prevent or Treat Diseases
Main Article Content
Abstract
In this investigation, suitable microbiological techniques and procedures were developed to study associative growth relationships among various probiotic cultures in order to maintain their intended component balance, without any one particular probiotic culture dominating others in a mixed culture by screening them ahead of time using several differential and selective bacteriological media to arrive at a highly-functional therapeutic pharmaceutical mixed probiotic culture. A simulated procedure has been developed mimicking the gradual pH transition of the human Gastro Intestinal tract starting from duodenum to the distal end of the colon. This procedure was developed to study the strain dominance phenomena of when mixed probiotic cultures are grown in a growth medium and sub-cultured through several transfers. The selection criteria applied is if a mixed probiotic culture that can maintain all its individual components through several transfers in the growth medium should be the choice of using it as a functional therapeutic probiotic blend. The results of the investigation proved that undue dominance does exist among strains of probiotics, which belongs not only to different genera, but also among members of the same species when they are grown together. The techniques outlined in this investigation can and has been applied clinically to study the composition of fecal Microbiota, to assess the GI tract health of the human being, and also to develop custom blends of proprietary pharmaceutically-superior therapeutic multiple mixed probiotic cultures to treat Dysbiosis, with choice than chance. The results also proved dominance among the members of mesophilic probiotic species of Lactococcus is more prevalent than thermophilic probiotics belonging to the genus Streptococcus and Lactobacillus. It illustrates that multiple mixed strain probiotic cultures have to be manufactured - for therapeutic purpose - only after determining their associative growth relationships in order to eliminate undue dominance of one particular probiotic culture over another in a mixed culture, and also subsequently in the GI tract of humans after ingestion. Using the microbiological techniques and procedures developed in this investigation, the compositions of novel mixed-strain probiotic cultures outlined in US Patent 11,077,052 B1 have been evaluated and proven that probiotic components used were compatible with no undue domination, thus successfully curing viral and bacterial infections through optimized Microbiota.
Article Details
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
2. Reddy MS, Reddy DRK. Therapeutic probiotics for cancer reduction. AAPI journal/ May/ June. 2015: 55-56.
3. Reddy MS, Reddy DRK. Probiotics, biotechnology, and Ayurvedic herbs - complementary and alternative medicine. AAPI Journal / May/ June. 2004: 32-33.
4. Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol. 2015;31(1):69. doi:10.1097/MOG.0000000000000139. -Doi-PMC-PubMed
5. FAO/WHO. Report on joint FAO/WHO. Expert consultation on evaluation of health and nutritional properties of probiotics in food including powdered milk with live lactic acid bacteria. 2001. (Google scholar). http://www.fao.org/3/a0512e/a0512e.pdf
6. Code of Federal Regulations of Food and Drug. Published by office of the Federal Register, National Archives and Records Administration, U.S. Government printing office, Washington, D.C., USA. 2001. http://bookstore.gpo.gov
7. Joint FAO/WHO Working group report on drafting guidelines for the evaluation of probiotics in food. Ontario: 2002. https://www.who.int/foodsafety/fs_ management/ en/probiotic_guidelines.pdf
8. Anukam KC, Reid G. Probiotics: 100 Years (1907-2007) after Elie Metchnikoff’s Observation. Communicating Current Research and Educational Topics. Trends in Applied Microbiology 1907; 466-474.
9. Reddy MS. Probiotics: Genesis, current definition, and proven therapeutic properties. JAAPI. 2021; 1 (2): 18 - 26.
10. Metchnikoff E. The prolongation of life. Optimistic studies. London: Butterworth-Heinemann. 1907. https://www. gutenberg.org/ebooks/51521
11. Reddy MS, Reddy DRK.Development of multiple mixed strain probiotics for “Probiotic therapy “ under clinical conditions, to prevent or cure the deadly hospital acquired infections due to Clostridium difficile (C. diff) and Methicillin Resistant Staphylococcus aureus (MRSA). Int J Pharma Sci Nanotech. 2016; 9 (3): 3256- 3281.
12. Reddy MS. Immunomodulatory effect of “ Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy “ to cure or prevent hospital acquired (Nosocomial) infections due to Clostridium difficile (C. diff), other pathogenic bacteria and autoimmune diseases. Int J Pharma Sci Nanotech. 2018; 11(1): 3937- 3949.
13. Hooper LV, Littman DR, Macpherson AJ. Interactions between the microbiota and the immune system. Science. 2012;336(6086):1268–1273. doi: 10.1126/science.1223490. - DOI - PMC - PubMed
14. Mallina R, Craik J, Briffa N, Ahluwalia V, Clarke J, Cobb A. Probiotic containing Lactobacillus casei, Lactobacillus bulgaricus, and Streptococcus thermophiles (ACTIMEL) for the prevention of Clostridium difficile associated diarrhoea in the elderly with proximal femur fractures. J Infect Public Health. 2018;11(1):85–88. doi: 10.1016/j.jiph.2017.04.001. - DOI - PubMed
15. Allen SJ, Jordan S, Storey M, Thornton CA, Gravenor MB, Garaiova I et al. Probiotics in the prevention of eczema: a randomised controlled trial. Archives of Disease in Childhood. 2014;archdischild-2013-305799. - PMC - PubMed
16. Anderson JW, Gilliland SE. Effect of fermented milk (yogurt) containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans. J Am Coll Nutrition 1999; 18:43-50.DOI: 10.1080/07315724.1999.10718826.
17. Reddy MS, Reddy DRK. An insight into the 2016 Best Medical Award-Winning Breakthrough Microbial and Nanotechnology based discovery of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy, to successfully treat the Nosocomial infections. Nano Technol Nano Sci.2017;1(1): 2-5.
18. Reddy MS. Immunomodulatory effect of “Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy” to cure or prevent hospital acquired nosocomial infections due to Clostridium difficile (C. diff), other pathogenic bacteria, and autoimmune diseases. Int J Pharma Sci Nano Tech. 2018;11:3937-3949.
19. SoSS, Wan ML, El-Nezami H. Probiotics-mediated suppression of cancer. Curr Opi Oncol. 2017;29(1):62–72. doi:10.1097/CCO.0000000000000342. - DOI - PubMed
20. Kich DM, Vincenzi A, Majolo F. Volken de Souza CF, Goettert MI: Probiotic: effectiveness nutrition in cancer treatment and prevention. Nutr Hosp. 2016;33(6):1430–1437. doi: 10.20960/nh.806. - DOI - PubMed
21. Hirayama K, Rafter J. The role of probiotic bacteria in cancer prevention. Microb Infect. 2000;2(6):681–686. doi: 10.1016/S1286-4579(00)00357-9. - DOI - PubMed
22. Reddy, MS. Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Adjuvant Cancer Therapy, to complement immune check point therapy and other traditional cancer therapies, with least autoimmune side effects through eco- balance of human Microbiome. Int J Pharma Sci Nanotech. 2018; 11 (6): 4295- 4317.
23. Nagata S, Chiba Y, Wang C, Yamashiro Y. The effects of the Lactobacillus casei strain on obesity in children: a pilot study. Beneficial Microb. 2017;8(4):535–543. doi: 10.3920/BM2016.0170. - DOI - PubMed
24. Park M, Kwon B, Ku S, Ji G. The efficacy of bifidobacterium longum BORI and lactobacillus acidophilus AD031 probiotic treatment in infants with rotavirus infection. Nutrients. 2017;9(8):887. doi: 10.3390/nu9080887. - DOI - PMC - PubMed
25. Acurcio L, Sandes S, Bastos R, Sant’Anna F, Pedroso S, Reis D, Nunes Á, Cassali G, Souza M, Nicoli J. Milk fermented by Lactobacillus species from Brazilian artisanal cheese protect germ-free-mice against Salmonella Typhimurium infection. Beneficial Microb. 2017;8(4):579–588. doi: 10.3920/BM2016.0163. - DOI - PubMed
26. Reddy MS. Scientific and medical research on Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy and its influence on assisting to cure or prevent the nosocomial infections, synergistically enhancing the conventional cancer therapies, as an adjuvant, and its possible potential to prevent or cure COVID -19 novel Coronavirus infection by balancing the intestinal Microbiota and Microbiome through modulation of the human immune system. Int J Pharma Sci Nanotech. 2020; 13(3): 4876- 4906. https://doi.org/10.37285/ijpsn.2020.13.3.3.
27. Reddy MS, Reddy DRK. Isolation and the determination of the major principle or causative agent behind the 2016 published breakthrough discovery of Dr. M. S. Reddy’s “ Multiple Mixed Strain Probiotic Therapy “, in successfully treating the lethal hospital acquired infections due to Clostridium difficile (C. diff) and Methicillin Resistant Staphylococcus aureus (MRSA). Int J Pharma Sci Nanotech. 2016; 9 (6): 3556-3566. https://doi.org/10.37285/ijpsn.2016.9.6.7
28. Reddy MS. Selected Multiphase Treatment for Coronavirus Respiratory Infections. US Patent Number 11,077,052 B1. 2021: 1-31.
29. Reddy MS. The Role of Prokaryotic (Probiotic) Produced Megamicro RNAs (memiRNAs) to Prevent or Cure Viral and Nosocomial Infections, Certain Cancers, in Conjunction with Probiotic Induced Eukaryotic Micro RNAs (miRNAs). Medical Research Archives, [online]. 2024; 12 (12): 1-21. https://doi.org/10.18103/mra.v12i12.6179.
30. Gilliland SE, Sandine WE, and Vedamuthu ER. Acid producing Microorganisms. Compendium of Methods for the Examination of Foods. American Public Health Association, Washington- D.C. 1984; Pages: 184-196.
31. Reddy MS, Vedamuthu ER, Washam CJ, Reinbold GW. Differential agar medium for separating Streptococcus lactis and Streptococcus cremoris. Appl Microbiol. 1969; 198: 755-759.
32. Reddy MS, Vedamuthu ER, Washam CJ, Reinbold GW. Agar medium for differential enumeration of lactic Streptococci. Appl Microbiol. 1972; 24: 947- 952.
33. Reddy MS, Vedamuthu ER, Reinbold GW. A differential broth for separating the lactic streptococci. J Milk Food Technol. 1971; 34: 43-45.
34. Lee SY, Vedamuthu ER, Washam CJ, Reinbold GW. An agar medium for the differential enumeration of yogurt starter bacteria. J. Milk Food Technol. 1974; 37: 272-276.
35. Malik AC, Reinbold GW, Vedamuthu ER. An evaluation of the taxonomy of Propionibacterium. Canadian Journal of Microbiology. 1968; 14: 1185-1191.
36. Hettinga DH, Vedamuthu ER, Reinbold GW. Pouch Method for Isolation and Enumerating Propionibacteria. J. Dairy Sci. 1968; 51: 1707-1709.